In patients with moderate peripheral artery disease, use of GLP-1 RAs increases the likelihood of more favorable cardiovascular and major limb outcomes.

Dr L’Erario discusses neurologic care for TGD patients, highlighting key challenges, best practices, & steps toward more inclusive treatment.

The FDA has granted Fast Track designation to nadunolimab to treat patients with previously untreated metastatic pancreatic ductal adenocarcinoma.